The announcement of iBio's research collaboration with the National Institute of Allergy and Infectious Diseases to develop a Lassa fever vaccine has a direct positive impact on the company's share price. Investors are likely to view this partnership as a potential growth opportunity for iBio, leading to increased demand for its shares and a higher stock price in the short term.